Tobias G.
- Country
- Germany
- Department
- Clinic for Haematology and Oncology
Research Overview
- Randomized phase II trial for patients with newly diagnosed low-risk multiple myeloma to evaluate the benefit of 6 cycles of isatuximab with lenalidomide/bortezomib/dexamethasone (I-VRD) followed by maintenance therapy with lenalidomide and isatuximab randomized in comparison with therapy consisting of 3 cycles of I-VRD followed by one cycle of high-dose therapy and maintenance therapy with lenalidomide and isatuximab
- INDIE: Phase II Trial of Individualized Immunotherapy in Early-Stage Unfavorable Classical Hodgkin Lymphoma
- Efficacy and Safety Comparison of Obinutuzumab-Venetoclax vs. Obinutuzumab-Chlorambucil in Untreated CLL with Comorbidities
Data & Insights
Has run more than one trial at 264 of 582 partner sites.
Specializations
Hematologic Malignancies
The investigator concentrates on a broad spectrum of blood cancers, including Acute Lymphoblastic Leukemia, Chronic Myeloid Leukemia, Chronic Lymphocytic Leukemia, Multiple Myeloma, and various forms of Non‑Hodgkin Lymphoma such as diffuse large B‑cell lymphoma and mantle‑cell lymphoma.
- Acute Lymphoblastic Leukemia (Ph+)
- Chronic Myeloid Leukemia
- Chronic Lymphocytic Leukemia (high‑risk)
- Multiple Myeloma
- Diffuse Large B‑Cell Lymphoma
These efforts aim to improve survival and disease control across diverse hematologic entities.
Targeted Molecular Therapies
Research activities emphasize agents that inhibit specific oncogenic pathways, notably BCR‑ABL1 inhibitors, Bruton’s Tyrosine Kinase (BTK) inhibitors, and novel proteasome inhibitors for myeloma.
- BCR‑ABL1 inhibition
- BTK inhibition
- Proteasome inhibition
- Combination of targeted agents
- Resistance mechanisms
The focus is on precision targeting of driver mutations to achieve deeper molecular responses.
Immunotherapy and Checkpoint Modulation
Investigator‑led studies explore immune‑based strategies, including PD‑1 blockade, CD20 monoclonal antibodies, and bispecific constructs for lymphoma and myeloma.
- PD‑1 inhibition
- CD20 directed antibodies
- Bispecific T‑cell engagers
- Checkpoint inhibitor combinations
- Immune‑related safety profiling
These approaches seek to harness the immune system for durable tumor control.
Solid Tumor Oncology
The clinical portfolio also covers major solid cancers such as Colorectal Cancer, Pancreatic Ductal Adenocarcinoma, Non‑Small Cell Lung Cancer, and Prostate Cancer, with emphasis on peri‑operative and adjuvant strategies.
- Colorectal carcinoma
- Pancreatic ductal adenocarcinoma
- Non‑Small Cell Lung Cancer
- Prostate carcinoma
- Neoadjuvant and adjuvant therapy optimization
Efforts target disease‑free survival and organ preservation in these malignancies.
Personalized and MRD‑Driven Strategies
Innovative work integrates minimal residual disease (MRD) assessment and molecular profiling to tailor treatment duration and intensity across hematologic and solid tumor indications.
- MRD‑guided therapy adaptation
- Genomic risk stratification
- Biomarker‑driven patient selection
- Adaptive trial designs
- Integration of ctDNA monitoring
This personalized approach aims to maximize efficacy while minimizing unnecessary exposure.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.